Answers are grounded in this paper and cite their sources.
Systematic review identifies SNPs affecting drug response in inflammatory bowel disease, suggesting precision medicine implications.
Background: 3' UTR SNPs on miRNA binding site alterations. Method: The study utilized a systematic literature review to identify genes influencing drug response in IBD, followed by SNP detection. SNPs were filtered based on population frequencies using global databases (gnomAD, ExAC) and Iranome for region-specific data. Structural and functional impacts of missense variants were evaluated using in silico tools and protein domain analysis via InterPro and UniProt. Additionally, molecular dynamics simulation indicated structural changes in HFE gene variants, RNA-seq data analyzed differential gene expression, and miRNASNP-v3 predicted miRNA binding site alterations in 3' UTR regions. Result: H63D variant, suggesting functional disruption. Conclusion: SNPs are identified as pivotal markers for personalized treatment strategies. Computational findings highlight their clinical potential, emphasizing the need for experimental validation to advance precision medicine and improve therapeutic outcomes and quality of life in IBD management.
No takes yet. Share an insight, caveat, or question.
Kazemifard et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: